Differentiation of the Electrophysiological Effects on the Atrial Myocardium Between the Pure Na Channel Blocker, Pilsicainide, and Flecainide

Authors: Masashi Kanemoto1; Akihiko Shimizu1; Toshihiko Yamagata1; Masahiro Esato1; Takeshi Ueyama1; Yasuhiro Yoshiga1; Hiroyuki Kakugawa1; Ryousuke Kametani1; Noriko Inoue1; Akira Sawa1; Masunori Matsuzaki2

Source: Cardiovascular Drugs and Therapy, Volume 18, Number 4, July 2004 , pp. 295-303(9)

Publisher: Springer

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

The purpose of this study was to identify the difference between the pure Na channel blocker, pilsicainide and Ic-antiarrhythmic drug, flecainide, on the atrial electrophysiological characteristics.

Methods: The subjects consisted of 24 patients (48 ± 12 years-old: P-group) in whom pilsicainide was administrated intravenously (1 mg/kg/10 min) and 31 patients (47 ± 15 years-old: F-group) in whom flecainide was administrated intravenously (2 mg/kg/10 min). The atrial effective refractory period (ERP-A), intra-atrial conduction time (CT), max intra-atrial conduction delay (Max CD), repetitive atrial firing zone (RAFZ), fragmented atrial activity zone (FAZ) and intra-atrial conduction delay zone (CDZ) were measured before and after the drugs.

Results: Pilsicainide and flecainide significantly prolonged the ERP-A (211 ± 27 msec to 246 ± 39 msec; p < 0.001, 217 ± 25 msec to 244 ± 33 msec; p < 0.001, respectively) and CT (121 ± 33 msec to 149 ± 43 msec; p < 0.001, 122 ± 22 msec to 153 ± 27 msec; p < 0.001, respectively) to the same degree. However, the Max CD was shortened by pilsicainide, but not by flecainide. The RAFZ, FAZ and CDZ decreased in the P-group (21 ± 25 msec to 4 ± 10 msec; p < 0.01, 24 ± 24 msec to 14 ± 18 msec; p < 0.05, 56 ± 29 msec to 43 ± 32 msec, p < 0.05, respectively), but not in the F-group. Conclusions: The effects of atrial conduction delays may differ between pilsicainide and flecainide. Further examination will be needed to explain this mechanism.

Keywords: sodium channel blocker; pilsicainide; flecainide; antiarrhythmic drug; atrial vulnerability

Document Type: Research article

DOI: 10.1023/B:CARD.0000041249.35724.da

Affiliations: 1: Division of Cardiovascular Medicine, Yamaguchi University Graduate School of Medicine 2: Division of Cardiovascular Medicine, Yamaguchi University Graduate School of Medicine, Email: masunori@yamaguchi-u.ac.jp

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$47.00 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A